QR Pharma is developing compounds for Alzheimer's (AD) disease and Parkinson's disease (PD):
| Posiphen® | APP/Aß and aSyn translational inhibition for early AD and PD Phase II clinical stage |
| BNC | Butyrylcholinesterase inhibition for moderate to severe AD IND Phase I clinical stage |
At QR Pharma, we believe that success depends on innovative research and solid development resulting in a quality product, developed efficiently and effectively.
QR Pharma is considering partnerships to maximize the commercial potential of its product pipeline. Ideal partners will have an established CNS market franchise and a commitment to innovative products.
QR's strategy is to take the two later stage clinical compounds, bring them back into the clinic to show efficacy and find a corporate partner.